Merck Animal Health will acquire TARGAN, according to an announcement reported by Feedstuffs. The company confirmed the deal in a notice that names TARGAN as the acquisition target.

The transaction places TARGAN, a technology-focused animal health firm, inside one of the largest veterinary pharmaceutical and animal health businesses in the world. Merck Animal Health has not disclosed further transaction terms in the reported notice.

What does the acquisition cover?

TARGAN joins Merck Animal Health as an acquired entity. The reported announcement establishes the buyer and the target but provides no purchase price, closing date, or regulatory review timeline.

For veterinary practices and poultry producers, the immediate practical change is ownership: TARGAN's products and services will now sit within Merck Animal Health's commercial structure.

Why is Merck Animal Health buying?

Large animal health manufacturers have spent several years acquiring technology firms to widen their portfolios beyond pharmaceuticals. This deal follows that pattern, moving an independent technology company under a major industry buyer.

The acquisition signals continued consolidation across the animal health sector, where scale and distribution networks increasingly determine which products reach farms and clinics.

What happens next?

The parties have announced the deal; completion will depend on standard closing conditions. Producers and veterinarians who use TARGAN products should watch for integration details, pricing, and support-channel changes as Merck Animal Health absorbs the business.

Industry observers will look for Merck Animal Health to confirm closing terms and explain how TARGAN's technology fits its existing animal health portfolio in the months ahead.

By Daniel Okafor for The Vet Scope